Page contentsPage contents Key facts Decision Key facts Active substance Fostamatinib Therapeutic area Other Decision number P/0195/2018 PIP number EMEA-001196-PIP02-17 Pharmaceutical form(s) Film-coated tablet Condition(s) / indication(s) Treatment of idiopathic thrombocytopenic purpura as a model for immunomodulation Route(s) of administration Oral use Contact for public enquiries Rigel Pharmaceuticals Ltd E-mail: dvance@rigel.comTel. +44 (0)1603 693204 Decision type W: decision granting a waiver in all age groups for all conditions or indications Compliance check done No Decision P/0195/2018: EMA decision of 17 July 2018 on the granting of a product specific-waiver for fostamatinib (EMEA-001196-PIP02-17)Adopted Reference Number: EMA/376000/2018 English (EN) (70.2 KB - PDF)First published: 27/11/2018 View Share this page